Gunderson Dettmer represented Denmark-based client Reshape Biotech, a robotic technology developer, in its $20 million Series A financing led by European VC firm Astanor Ventures. Reshape has developed a robotic imaging system replete with software and AI models to help scientists track visual changes — such as color or cell-growth rates — from Petri dishes and similar plate formats. The new capital will be used to scale its business in the U.S.

In the announcement of the transaction, Reshape CEO Carl-Emil Grøn said, “Biology as a whole is transitioning from a science to an engineering discipline, and I think one of the biggest things that we want to do is make some of the very ‘intangible’ — how does an object grow, how does it behave? — easier to describe. Ideally, we want to figure out how we make that translation layer between what happens in the real world, and what happens in your DNA.”

The Gunderson Dettmer deal team was led by Rich Hesp and included Jordana Douglas, Caitlin Walsh and Joel Diamond. 

Companies
Reshape Biotech
Astanor Ventures